Clinical stage medicine developer RegeneRx Biopharmaceuticals Inc (OTCMKTS:RGRX), which is primarily concerned with tissue protection and repair products, saw its stock take a beating on Wednesday.
The stock tanked by as much as 7% yesterday after the company announced the results from an independent research paper which indentified Thymosin Beta 4 or TB4 as a possible treatment for critical kidney injuries and for possibly reducing the mortality among patients who might be suffering from sepsis. It goes without saying that it was a significant development for the company but at the same time it should be noted that investors did not really express much excitement about it.
It is going to be interesting to see if the tide turns for the RegeneRx stock over the course of the coming days in light of the findings from the research paper. In this context, it should be pointed out that the company is mainly involved in developing novel therapeutic peptides and one of the peptides that it is working on is TB4.
Hence, the latest findings in the independent research paper could well prove to be a boost for the company. At this point in time, investors could do well to keep an eye on the company’s progress.
